No Data
No Data
Baiyang Co., Ltd. (002696.SZ): There is currently no synthetic biotechnology
Gelonghui, May 7 | Baiyang Co., Ltd. (002696.SZ) said on the investor interactive platform that the company currently has no synthetic biotechnology. The company's biological products processing business is an extension of the aquatic food processing business industrial chain. By fully exploiting and enhancing the value of tilapia by-products, the comprehensive utilization of aquatic product processing by-products is realized. The company uses fish skin and fish scales as raw materials to develop a series of biological products such as collagen and gelatin, which can be widely used in health products, cosmetics, food and other fields.
Baiyang Co., Ltd. (002696.SZ): Net loss of 3.7589 million yuan in the first quarter
Gelonghui, April 26, 丨 Baiyang Co., Ltd. (002696.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 507 million yuan, down 8.47% year on year; net profit attributable to shareholders of listed companies - 37.589 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 5.381 million yuan; basic earnings per share - 0.0109 yuan.
Baiyang Co., Ltd. (002696.SZ): The main business is feed and feed ingredients, aquatic food processing, and pelagic fishing
Gelonghui, March 7 | Baiyang Co., Ltd. (002696.SZ) said on the investor interactive platform that the company's main business is feed and feed ingredients, aquatic food processing, and pelagic fishing, and belongs to the marine industry sector under the Qingdao Guoxin Group. The company's shareholder, Qingdao Guoxin Group, established Guoxin Health Industry Co., Ltd. and strategically reorganized Chia Da Pharmaceutical (Qingdao) Co., Ltd. through its fund. It is its layout for biomedical and health industries with marine characteristics. Recently, it has signed strategic cooperation agreements with China Biopharmaceutical and Qingdao Marine Biomedical Research Institute in Qingdao. The previous agreement on the above acquisition project
Baiyang Co., Ltd. (002696.SZ): The domestic sales business currently includes two series of products: “Beifong” brand and “Qiao Yujia”
Gelonghui, Feb. 8 | Baiyang Co., Ltd. (002696.SZ) said on the investor interactive platform that the company's domestic sales business currently includes two series of products: “Beifong” brand and “Qiao Yujia”. Among them, the “Beifong” brand products already have varieties such as pulp-free black fish fillets, crispy fish fillets without pulp, and crispy fish fillets in hot pot; “Qiao Yujia” series products already have varieties such as pulp-free, peel-free pangasius fillets, and blackfish fillets without pulp; in addition, the company has also developed deep-processed products such as open back sea bass and golden mackerel. In recent years, the company has increased its market expansion efforts in the aquatic food business. Sales have increased, and related products have also won
Lacklustre Performance Is Driving Baiyang Investment Group, Inc.'s (SZSE:002696) 27% Price Drop
Baiyang Investment Group, Inc. (SZSE:002696) shareholders won't be pleased to see that the share price has had a very rough month, dropping 27% and undoing the prior period's positive performance.
Baiyang Co., Ltd. (002696.SZ): Pre-loss of 20 million yuan to 30 million yuan in 2023
Gelonghui, January 29丨Baiyang Co., Ltd. (002696.SZ) announced its 2023 annual results forecast. Net profit loss attributable to shareholders of listed companies during the reporting period was 20 million yuan to 30 million yuan, profit of 62.3388 million yuan for the same period last year; net profit loss after deducting non-recurring profit and loss of 30 million yuan to 40 million yuan, profit for the same period last year; basic earnings loss of 0.06 yuan/share per share - 0.09 yuan/share. Feed business: In 2023, fish prices were low due to heavy spring rain, low temperatures, and weak terminal demand
No Data